Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, November 2001, p. 3109-3112, Vol. 45, No. 11
Laboratoire de Bactériologie,
Faculté de Médecine Pitié-Salpêtrière,
Paris, France
Received 26 March 2001/Returned for modification 4 June
2001/Accepted 8 August 2001
Mice infected in the left hind footpad with 5 log10
acid-fast bacilli of Mycobacterium ulcerans were divided
into an untreated control group and 17 treatment groups that received
one of the following regimens for 4 weeks (all doses in milligrams per
kilogram): 100 mg of azithromycin (AZM), 100 mg of clarithromycin
(CLR), or 50 mg of AZM for a duration of 5 days a week (daily), three times a week, or once weekly. In addition, the following regimens were
administered daily: 100 mg of telithromycin (TLM), sparfloxacin (SPX),
or moxifloxacin (MOX); 200 mg of levofloxacin (LVX); 100 mg of
streptomycin (STR) or amikacin (AMK); 10 mg of rifampin (RIF); and the
combination of 10 mg of RIF and 100 mg of AMK (RIF+AMK). After
completion of treatment, mice were observed for 30 weeks. The
effectiveness of treatment regimens was assessed in terms of the delay
in median time to footpad swelling in treated mice compared with that
in the untreated controls. Clear-cut bactericidal activity, i.e., an
observed delay in footpad swelling that exceeded the period of
treatment, was observed in the STR-, AMK-, and RIF+AMK-treated mice.
However, all mice treated with either AMK or STR alone had swollen
footpads before the end of the 30-week observation period, suggesting
regrowth of M. ulcerans. In contrast, 50% of the
mice treated with the RIF+AMK combination exhibited no lesion even after 30 weeks, suggesting cure. The remaining regimens could be
assigned to one of three groups: (i) no activity (50 mg of AZM, 100 mg
of AZM thrice weekly, TLM, and LVX); (ii) bacteriostatic activity, i.e., a delay in footpad swelling shorter than
the 4-week treatment duration (100 mg of AZM daily or once weekly, CLR
thrice or once weekly, and MOX); or (iii) weak bactericidal activity (CLR daily and SPX). The RIF+AMK combination and possibly RIF+STR warrant further study for the treatment of M. ulcerans
infection in humans.
Mycobacterium ulcerans,
the only toxin-producing mycobacterial species (5) is
responsible for Buruli ulcer (BU), the third most prevalent
mycobacterial disease throughout the world (20). Over the
past 10 years, an increasing incidence of BU has been reported in
several West African countries (6, 8) and Australia (4) and is now reported in most of sub-Saharan Africa,
Central and South America, India, Southeast Asia, and Papua New Guinea (20).
In vitro, M. ulcerans is susceptible to several
antimicrobials, including rifampin (RIF), clarithromycin (CLR),
streptomycin (STR), amikacin (AMK), sparfloxacin (SPX), and clofazimine
(1, 11, 13, 14, 19). However, the clinical response of
humans with BU to various antimicrobial regimens containing these drugs have not confirmed in vitro studies so that, to date, BU treatment still relies on extensive surgical excision of the lesions followed by
skin grafting (20).
In a previous study, the mouse footpad model of Fenner (3)
was used to assess the in vivo activity of several drugs against M. ulcerans (2). CLR, for which in vitro
activity against M. ulcerans has been demonstrated
(11), exhibited only bacteriostatic activity in the mouse.
Azithromycin (AZM), a macrolide derivative with long half-life
(7), and telithromycin (HMR 3647) (TLM), a semisynthetic
ketolide with demonstrated in vitro activity (12), were
considered of potential interest for the treatment of BU. Therefore,
the in vivo activity of these two drugs against M. ulcerans
in mice was compared with that of the reference macrolide CLR, with
three fluoroquinolones, and with rifampin (RIF), streptomycin (STR),
and amikacin (AMK), all drugs with demonstrated in vivo experimental
activity against M. ulcerans (2). The
antimicrobial activities of the drugs were measured by the ability of
each drug regimen given at different time intervals over 4 weeks to
prevent or delay swelling of mouse footpads infected with M. ulcerans.
Antimicrobial agents.
AZM was generously provided by Pfizer,
Orsay, France; CLR by Abbott, Rungis, France; AMK by
Bristol-Myers-Squibb, Paris, France; RIF, TLM, LVX, and SPX by Aventis,
Antony, France; MOX by Bayer, Puteaux, France; and STR by the hospital pharmacy.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.11.3109-3112.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Activities of New Macrolides and Fluoroquinolones
against Mycobacterium ulcerans Infection in
Mice
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
M. ulcerans strain. The Cu001 strain of M. ulcerans used in the present study was isolated from a BU excised from a patient in Adzopé, Côte d'Ivoire, in June 1996. The strain has been maintained by successive subcultures in footpads of BALB/c mice.
Mouse model, infection, and treatment. Six-week-old female BALB/c mice (Janvier Breeding Center, Le Genest-Saint-Isle, France), weighing 18 to 20 g were housed in the animal facility for 1 week before infection. Then, each mouse was infected in the left hind footpad with 5 log10 acid-fast bacilli (AFB) of M. ulcerans contained in a volume of 0.03 ml (2, 15) and started on a 4-week treatment regimen 1 week after infection. The short duration of treatment was chosen in order to rapidly discriminate bactericidal drugs from bacteriostatic drugs that may be useful as second-line drugs or in combination with bactericidal drugs.
The 220 infected mice were allocated randomly to an untreated control group of 30 mice or to one of 17 treatment groups. The first two treatment groups of 20 mice each were given 100 mg (all doses are per kilogram) of either CLR or AZM 5 days a week (daily). Treatment groups 3 to 6, each with 10 mice, were also given 100 mg of CLR or AZM, but delivered either thrice or once weekly. Ten mice in each of treatment groups 7 to 9 were given 50 mg of AZM administered either 5 days a week or thrice or once weekly. The remaining eight groups, of 10 mice each, were given daily 100 mg of either TLM, SPX, or MOX; 200 mg of LVX; 100 mg of either STR or AMK; 10 mg of RIF; and the combination of 10 mg of RIF and 100 mg of AMK (RIF+AMK). AMK and STR were injected subcutaneously. All other drugs were administered orally with an esophageal canula (gavage). On completion of treatment, 10 mice treated daily with 100 mg of either CLR or AZM were sacrificed to determine AFB and CFU counts in the inoculated footpads. All other mice were kept under observation for 30 additional weeks.Assessment of M. ulcerans growth and treatment activity. The growth of M. ulcerans in the inoculated footpads was defined as occurrence of footpad swelling combined with an AFB count equal or superior to 5 log10 per footpad.
The infected footpads of 10 untreated control mice were harvested for baseline and CFU counts 1 week after infection, i.e., the day of treatment onset. Four weeks later, on completion of treatment, AFB and CFU counts were performed on infected footpads from 10 untreated control mice and 10 mice treated daily with 100 mg of either CLR or AZM. All other mice were examined for swelling of the footpad on a weekly basis. As soon as the footpad became swollen, the mouse was sacrificed for AFB and CFU counts. AFB counts were performed microscopically according to the method developed by Shepard and McRae for enumerating Mycobacterium leprae in the footpad of the mouse (17). CFU counts were performed by plating appropriate dilutions of the harvested footpad onto Löwenstein-Jensen medium incubated at 32°C for 4 months (2). Because of bacterial contamination of cultures in a previous experiment (2), footpads were carefully disinfected with chlorhexidine before harvesting M. ulcerans for AFB and CFU counts. The activity of each treatment was assessed in terms of delay in median time to footpad swelling (and AFB count
5
log10) in treated mice compared with untreated
control mice, using the kinetic method developed by Shepard for
assessing activity of antileprosy drugs (16). A drug was
defined as having no antimicrobial activity if the time to footpad
swelling in treated mice was not significantly different from that in
untreated control mice. A drug was defined as bacteriostatic if the
additional time to footpad swelling induced by the treatment was
greater than that in the control mice but less than the duration of
treatment (i.e., 4 weeks). A drug, alone or in combination, was labeled
bactericidal if the additional time to footpad swelling was
significantly longer than the 4-week duration of treatment, i.e., the
longer the additional time, the more bactericidal the drug.
Statistical analysis.
Survival analysis, with the swollen
footpad as the measurement, was done by the Kaplan-Meier (KM) method
(10). The log rank test was used to determine the level of
statistical significance when comparing survival curves of the
different groups. P values are two-tailed, and
P 
0.05 was considered statistically significant.
| |
RESULTS |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
Mortality. Among all mice, there was a single unexplained spontaneous death before footpad swelling in the group of mice treated daily with AZM at 50 mg/kg.
Footpad lesions. (i) Control mice
No footpad
swelling occurred before the sacrifice of 10 mice 1 week after
inoculation. The first lesions appeared at the third week (W3). At W5,
four mice had swollen footpads before the sacrifice of 10 additional
mice. All 10 remaining mice had swollen footpads by W10. Swelling of
50% of the inoculated footpads (Fig. 1)
occurred by 6 weeks (95% confidence interval [CI95], 5 to 7).
|
(ii) Treated mice.
Swelling of footpads (Table
1) began at W5 in mice treated with once
weekly AZM at 50 mg/kg, thrice weekly AZM at 100 mg/kg, and daily TLM
at 100 mg/kg. It began at W6 in mice treated with either thrice weekly
or daily AZM at 50 mg/kg, once weekly AZM at 100 mg/kg, once weekly CLR
at 100 mg/kg, and daily MOX at 100 mg/kg. Swelling began at W7 in mice
treated with daily AZM at 100 mg/kg and LVX at 200 mg/kg, and at W10 in
mice treated with either thrice weekly or daily CLR at 100 mg/kg, daily
SPX at 100 mg/kg, or TLM at 100 mg/kg. The footpad swelling began much
later in the remaining groups: W12 in mice treated with daily RIF, W15 in mice treated with daily AMK or STR, and W21 in mice treated with the
combination RIF+AMK.
|
Enumeration of AFB in footpads. In the control mice, the mean AFB count performed 1 week after inoculation was 5.7 log10, and 5.5 log10 4 weeks later. AFB counts were equal or superior to 5.2 log10 (median, 6.0; range, 5.2 to 6.8) in all treated mice with swollen footpads but one (AFB count, 4.7 for the once a week AZM at 50 mg/kg treatment group).
Enumeration of CFU in footpads. Despite disinfection before handling, all cultures were superinfected with Staphylococcus aureus or enterobacteria. As a result, CFU counts could not be assessed.
Comparative activity of different drug regimens. There was no statistically significant difference between KM curves drawn from the control mice and from mice treated with AZM at 50 mg/kg given once, three times, or five times a week (Table 1). Similarly, there was no statistically significant difference between KM curves drawn from the control mice and from the TLM-treated and LVX-treated mice.
In mice treated with 100 mg/kg of AZM once a week and 5 days a week, the median time to M. ulcerans growth (i.e., swelling plus AFB count >5 log10) was 1 week longer than in control mice. Although both KM curves were significantly different from control mice (P < 0.001), the activities of both regimens were considered poorly bacteriostatic. Similar conclusion can be drawn for MOX-treated mice, because the median time to M. ulcerans growth was only delayed by 2 weeks compared to control mice. The activities of CLR given once or thrice weekly and of daily LVX were slightly superior but still bacteriostatic, as the median time to swelling was only 3 or 4 weeks longer than in control mice. On the other hand, the activities of daily CLR and SPX regimens were considered only slightly bactericidal because the median time to M. ulcerans growth was 5 weeks longer than in control mice, i.e., 1 week longer than the duration of therapy. Finally, only RIF, AMK, STR, and, above all, the combination AMK+RIF had clear-cut bactericidal activities (Fig. 1). However, the KM curve drawn from the AMK+RIF-treated mice was significantly more favorable than those drawn from mice treated with RIF (P = 0.001), AMK, or STR alone (P = 0.02). In addition, there was no statistically significant difference between AMK and STR curves (P = 0.79).| |
DISCUSSION |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
CLR and AZM exhibited limited activity against M. ulcerans when tested by the kinetic method developed by Shepard (16) to assess the activity of antimicrobial drugs against M. leprae in the mouse footpad model. At a daily dose of 100 mg/kg, equipotent to 15 mg/kg in humans (21), CLR was weakly bactericidal, and AZM was bacteriostatic. These findings confirm previous data on CLR activity against M. ulcerans in the mouse (2). They also strongly suggest that AZM, a long-lasting macrolide of interest in the preventive therapy of Mycobacterium avium complex infection (9), cannot substitute for CLR in the curative treatment of M. ulcerans infection. Therefore, it is not possible to propose an easier-to-implement intermittent treatment with an AZM-containing regimen for the treatment of M. ulcerans infections.
Similar conclusions can be drawn for TLM (HMR 3647), a semisynthetic ketolide, as well as LVX and MOX, which have bacteriostatic activities. SPX had weakly bactericidal activity similar to that of CLR, and neither could be recommended as a first-line drug for the treatment of M. ulcerans infections. However, because of the short duration of treatment (4 weeks), we cannot rule out potential usefulness of the latter drugs when given in combination with the more bactericidal drugs.
Among drugs with bactericidal activity, RIF was clearly the least potent. After 4 weeks of treatment with daily RIF, the time to swelling of 50% of the footpads was only 2 weeks longer than that obtained with CLR or SPX. Like these latter two drugs, RIF cannot be considered a major drug against M. ulcerans infection. Actually, when tested with the kinetic method, only STR and AMK appeared to be major bactericidal drugs against M. ulcerans. Compared to that with RIF, the time to swelling of 50% of the footpads induced by the two drugs was delayed 2 weeks for AMK and 6 weeks for STR, the difference between the two drugs being insignificant when the entire curve was considered. However, even though both drugs exhibit clear bactericidal activities, their overall effect in a 4-week treatment regimen would discourage their suggested implementation in the field, since regrowth of M. ulcerans occurred in all animals.
The most effective drug regimen was the apparently synergistic combination of AMK+RIF that delayed the occurrence of lesions by at least 10 weeks compared to STR or AMK alone. In addition, 5 of the 10 mice treated for 4 weeks with the combination regimen were free of lesions 35 weeks after infection, or 31 weeks after treatment completion, suggesting that these mice might have been cured. Such findings are in accordance with the previous observation that RIF or AMK given for 8 weeks prevented footpad swelling in all treated mice up to 4 months after treatment completion (2), and with the observation of Stanford and Phillips (18) that treatment failure in mice treated with RIF alone was related to the duration of treatment, 1 month of treatment resulting in relapse and 3 months producing apparent cure.
This study also suggests that the STR+RIF combination is likely to be as effective as the AMK+RIF combination because STR appeared to be as active as AMK against M. ulcerans. Although not an ideal combination for field use because of the need for injection and the potential of drug toxicity, the STR+RIF and AMK+RIF combinations deserve to be tested in humans with BU, with the following two objectives: to determine the feasibility and acceptability and the minimal treatment duration for effectiveness. A clinical trial with both objectives is under way under the guidance of the World Health Organization Global Buruli Ulcer Initiative.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by a grant from Pfizer.
We thank Kingsley Asiedu for assistance and George Kubica for critical review of the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Laboratoire de Bactériologie, Faculté de Médecine Pitié-Salpêtrière, 91 Boulevard de l'Hôpital, 75634 Paris Cedex 13, France. Phone: (33) 1 40 77 97 46. Fax: (33) 1 45 82 75 77. E-mail: jacques_grosset{at}yahoo.com.
| |
REFERENCES |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
| 1. | Darie, H., S. Djakeaux, and A. Cautoclaud. 1994. Approche thérapeutique des infections à Mycobacterium ulcerans. Bull. Soc. Pathol. Exp. 87:19-21. |
| 2. |
Dega, H.,
J. Robert,
P. Bonnafous,
V. Jarlier, and J. Grosset.
2000.
Activities of several antimicrobials against Mycobacterium ulcerans infection in mice.
Antimicrob. Agents Chemother.
44:2367-2372 |
| 3. | Fenner, F. 1956. Pathogenic behavior of Mycobacterium ulcerans and Mycobacterium balnei in mouse and developing chick embryo. Am. Rev. Tuberc. 73:650-673[Medline]. |
| 4. | Flood, P., A. Street, P. O'Brien, and J. Hayman. 1994. Mycobacterium ulcerans infection on Phillip Island, Victoria. Med. J. Aust. 160:160[Medline]. |
| 5. |
George, K. M.,
D. Chatterjee,
G. Gunawardana,
D. Welty,
J. Hayman,
R. Lee, and P. L. Small.
1999.
Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence.
Science
283:854-857 |
| 6. | Josse, R., A. Guedenon, H. Darie, S. Anagonou, F. Portaels, and W. M. Meyers. 1995. Les infections cutanées à Mycobacterium ulcerans: ulcères de Buruli. Med. Trop. 55:363-373. |
| 7. |
Lode, H.,
K. Borner,
P. Koeppe, and T. Schaberg.
1996.
Azithromycin-review of key chemical, pharmacokinetic and microbiological features.
J. Antimicrob. Chemother.
37(Suppl. C):1-8 |
| 8. | Marston, B. J., M. O. Diallo, C. R. Horsburgh, Jr., I. Diomande, M. Z. Saki, J. M. Kanga, G. Patrice, H. B. Lipman, S. M. Ostroff, and R. C. Good. 1995. Emergence of Buruli ulcer disease in the Daloa region of Cote d'Ivoire. Am. J. Trop. Med. Hyg. 52:219-224. |
| 9. | Oldfield, E. C., W. J. Fessel, M. W. Dunne, G. Dickinson, R. M. Wallace, W. Byrne, R. Chung, K. F. Wagner, S. F. Paparello, D. B. Craig, G. Melcher, M. Zajdowicz, R. F. Williams, J. W. Kelly, M. Zelasky, L. B. Heifets, and J. D. Berman. 1998. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin. Infect. Dis. 26:611-619[Medline]. |
| 10. | Peto, R., M. C. Pike, P. Armitage, N. E. Breslow, D. R. Cox, S. V. Howard, N. Mantel, K. McPherson, J. Peto, and P. G. Smith. 1977. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br. J. Cancer 35:1-39[Medline]. |
| 11. |
Portaels, F.,
H. Traore,
K. De Ridder, and W. M. Meyers.
1998.
In vitro susceptibility of Mycobacterium ulcerans to CLR.
Antimicrob. Agents Chemother.
42:2070-2073 |
| 12. |
Rastogi, N.,
K. S. Goh,
M. Berchel, and A. Bryskier.
2000.
In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of CLR against slowly growing mycobacteria at pHs 6.8 and 7.4.
Antimicrob. Agents Chemother.
44:2848-2852 |
| 13. | Revill, W. D., R. H. Morrow, M. C. Pike, and J. Ateng. 1973. A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet ii:873-877. |
| 14. | Schroder, K. H. 1975. Investigation into the relationship of Mycobacterium ulcerans to M. buruli and other mycobacteria. Am. Rev. Respir. Dis. 111:559-562[Medline]. |
| 15. | Shepard, C. C. 1960. The experimental disease that follows the injection of human leprosy bacilli into foot pads of mice. J. Exp. Med. 112:445-454[Abstract]. |
| 16. | Shepard, C. C. 1967. A kinetic method for the study of the activity of drugs against Mycobacterium leprae. Int. J. Lepr. 35:429-436. |
| 17. | Shepard, C. C., and D. H. Mc Rae. 1968. A method for counting acid-fast bacteria. Int. J. Lepr. 36:78-82. |
| 18. |
Stanford, J. L., and I. Phillips.
1972.
Rifampicin in experimental Mycobacterium ulcerans infection.
J. Med. Microbiol.
5:39-45 |
| 19. |
Thangaraj, H. S.,
O. Adjei,
B. W. Allen,
F. Portaels,
M. R. Evans,
D. K. Banerjee, and M. H. Wansbrough-Jones.
2000.
In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans.
J. Antimicrob. Chemother.
45:231-233 |
| 20. | van der Werf, T. S., W. T. van der Graaf, J. W. Tappero, and K. Asiedu. 1999. Mycobacterium ulcerans infection. Lancet 354:1013-1018[CrossRef][Medline]. |
| 21. | Xiong, J. H., B. Ji, E. G. Perani, C. Petinon, and J. H. Grosset. 1994. Further study of the effectiveness of single doses of CLR and minocycline against Mycobacterium leprae in mice. Int. J. Lepr. 62:37-42. |
Antimicrobial Agents and Chemotherapy, November 2001, p. 3109-3112, Vol. 45, No. 11
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.11.3109-3112.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Chauty, A., Ardant, M.-F., Adeye, A., Euverte, H., Guedenon, A., Johnson, C., Aubry, J., Nuermberger, E., Grosset, J.
(2007). Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer (Mycobacterium ulcerans Disease). Antimicrob. Agents Chemother.
51: 4029-4035
[Abstract] [Full Text] -
Lefrancois, S., Robert, J., Chauffour, A., Ji, B., Jarlier, V.
(2007). Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-Amikacin. Antimicrob. Agents Chemother.
51: 645-650
[Abstract] [Full Text] -
Ji, B., Lefrancois, S., Robert, J., Chauffour, A., Truffot, C., Jarlier, V.
(2006). In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans.. Antimicrob. Agents Chemother.
50: 1921-1926
[Abstract] [Full Text] -
Goto, M., Nakanaga, K., Aung, T., Hamada, T., Yamada, N., Nomoto, M., Kitajima, S., Ishii, N., Yonezawa, S., Saito, H.
(2006). Nerve Damage in Mycobacterium ulcerans-Infected Mice: Probable Cause of Painlessness in Buruli Ulcer. Am. J. Pathol.
168: 805-811
[Abstract] [Full Text] -
Etuaful, S., Carbonnelle, B., Grosset, J., Lucas, S., Horsfield, C., Phillips, R., Evans, M., Ofori-Adjei, D., Klustse, E., Owusu-Boateng, J., Amedofu, G. K., Awuah, P., Ampadu, E., Amofah, G., Asiedu, K., Wansbrough-Jones, M.
(2005). Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans. Antimicrob. Agents Chemother.
49: 3182-3186
[Abstract] [Full Text] -
Okenu, D. M. N., Ofielu, L. O., Easley, K. A., Guarner, J., Spotts Whitney, E. A., Raghunathan, P. L., Stienstra, Y., Asamoa, K., van der Werf, T. S., van der Graaf, W. T. A., Tappero, J. W., Ashford, D. A., King, C. H.
(2004). Immunoglobulin M Antibody Responses to Mycobacterium ulcerans Allow Discrimination between Cases of Active Buruli Ulcer Disease and Matched Family Controls in Areas Where the Disease Is Endemic. CVI
11: 387-391
[Abstract] [Full Text] -
Dega, H., Bentoucha, A., Robert, J., Jarlier, V., Grosset, J.
(2002). Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in Mice. Antimicrob. Agents Chemother.
46: 3193-3196
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»